Business Context and Reporting Period
The provided filing is Aileron Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, not Rein Therapeutics, Inc. The company is a clinical-stage biopharmaceutical company focused on orphan pulmonary and fibrosis indications. In October 2023, Aileron acquired Lung Therapeutics, Inc. and shifted its focus from oncology and ALRN-6924 to LTI-03, LTI-01 and related preclinical programs.
- LTI-03: Phase 1b dose-ranging trial in idiopathic pulmonary fibrosis, with top-line data expected in the third quarter of 2024.
- LTI-01: Completed Phase 1b and Phase 2a studies for loculated pleural effusion; additional dose-ranging development is planned.
- The company has no approved products, no product sales revenue and no commercial sales or marketing infrastructure.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $4.0 million | $18.0 million | Down $14.0 million |
| General and administrative expense | $11.4 million | $9.7 million | Up $1.7 million |
| Restructuring and other costs | $0.9 million | $0 | Up $0.9 million |
| Total operating expenses | $16.3 million | $27.6 million | Down $11.4 million |
| Operating loss | $16.3 million | $27.6 million | Improved by $11.4 million |
| Net loss | $15.7 million | $27.3 million | Improved by $11.6 million |
| Net loss per share | $3.42 | $6.02 | Improved |
| Cash used in operating activities | $19.8 million | $24.9 million | Use decreased by $5.1 million |
| Cash and cash equivalents at year-end | $17.3 million | $5.2 million | Up $12.1 million |
The company reported no debt financing liabilities in the summarized balance sheet. Current liabilities were $4.4 million, total liabilities were $7.7 million, and the company had $91.4 million of Series X preferred stock classified as temporary equity. The accumulated deficit was $288.5 million.
Cash and cash equivalents increased primarily because of $15.8 million of net financing proceeds, $16.2 million of investing cash inflows and $19.8 million of operating cash use. The company stated that its cash was expected to fund operations into the fourth quarter of 2024 under its then-current operating plan, but the audited financial statements included a going-concern emphasis and management concluded that substantial doubt existed about continuing as a going concern.
Material Changes Versus the Prior Comparable Period
- Development of ALRN-6924 was terminated in February 2023 after review of Phase 1b chemoprotection data. The company reduced its workforce from nine to three employees and recorded $0.9 million of restructuring charges.
- Research and development expense declined substantially because of the termination and completion of prior ALRN-6924 programs, partially offset by expenses incurred by Lung after the acquisition.
- General and administrative expense increased because of acquisition-related professional fees.
- The Lung acquisition added $79.2 million of indefinite-lived intangible assets and $6.3 million of goodwill to the balance sheet.
- The acquisition and related financing resulted in the issuance of 19,903 Series X preferred shares to Lung stockholders, 4,707 Series X preferred shares to investors and warrants for 2,353,500 common shares.
- The financing generated approximately $18.4 million of gross proceeds and $17.5 million of net proceeds after issuance costs.
- At December 31, 2023, 24,610 Series X preferred shares were outstanding and convertible into approximately 24.6 million common shares, subject to beneficial ownership limitations and stockholder approval.
Guidance, Outlook, Commentary and Risks
- Management expected to report top-line Phase 1b LTI-03 data in the third quarter of 2024.
- Management expected to pursue an additional Phase 2 dose-ranging study for LTI-01, potentially using a lower dose and modified efficacy assessment.
- The company expects continued operating losses and requires substantial additional capital to complete clinical development and pursue commercialization.
- The company has no committed external funding source. Additional equity, debt, collaboration, licensing or other financing could dilute stockholders, restrict operations or require the company to relinquish product rights.
- LTI-03 previously produced treatment-related cough and reversible airway-obstruction events at higher doses in Phase 1a testing, including moderate and severe events in a 40 mg cohort. Lower-dose cohorts did not produce moderate, severe or serious treatment-related events.
- The LTI-01 Phase 2a trial did not show a statistically significant difference in its primary treatment-failure endpoint, and only 40 patients completed enrollment because of COVID-19-related delays and limited drug shelf life.
- The company relies on third parties for clinical research, manufacturing and supply. LTI-01 has a sole drug-substance manufacturer and the company has non-cancellable manufacturing commitments of $2.3 million, plus $1.4 million of prepaid manufacturing balances.
- Management identified material weaknesses in internal control over financial reporting, primarily involving the Lung acquisition accounting, segregation of duties, review documentation and timely preparation of financial statements. Disclosure controls were deemed ineffective as of December 31, 2023.
- The company faces Nasdaq compliance risk, substantial potential dilution from preferred stock, options and warrants, and concentrated ownership. On a fully diluted basis, Bios-affiliated holders could own approximately 45.8% of common stock, according to the filing.
- Subsequent to year-end, stockholders approved conversion of the Series X preferred stock and an increase in authorized common shares to 100 million. On March 5, 2024, approximately 12.1 million common shares were issued upon automatic conversion of 12,087 preferred shares.
Most Important Facts to Verify
- Confirm that the intended issuer is Aileron Therapeutics, Inc., ticker ALRN, rather than Rein Therapeutics, Inc.
- Verify the company’s current cash balance, monthly cash burn and financing completed after the April 15, 2024 filing date.
- Review whether the planned third-quarter 2024 LTI-03 data were reported and assess safety, biomarker activity and patient enrollment.
- Evaluate the design, timing and funding of the next LTI-01 clinical trial given the non-significant Phase 2a primary endpoint.
- Assess dilution from the Series X preferred stock, the $4.89-per-share warrants, assumed options and other outstanding warrants.
- Monitor remediation of the material weaknesses and any subsequent restatement, audit qualification or control deficiencies.
- Reconcile the going-concern disclosure with subsequent financing activity and determine whether the company has sufficient capital for at least the next twelve months.